imiquimod has been researched along with plx 4720 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bellmann, L; Brinckerhoff, CE; Cappellano, G; Mullins, DW; Ortner, D; Prokopi, A; Schachtl-Riess, JF; Seretis, A; Stoitzner, P; Tripp, CH | 1 |
1 other study(ies) available for imiquimod and plx 4720
Article | Year |
---|---|
A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imiquimod; Indoles; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Male; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mutation; Natural Killer T-Cells; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; T-Lymphocytes; Toll-Like Receptor 7 | 2020 |